Global Myelofibrosis Treatment Market Will Reach USD 971.5

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
69
Global Myelofibrosis Treatment Market Will Reach USD 971.5 Million By 2024: Zion Market Research

New York, NY, July 24, 2018 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Myelofibrosis Treatment Market by Diagnosis Type (Gene Mutation Analysis, Bone Marrow biopsy, Imaging Test, and Blood Tests), by Treatment Type (Chemotherapy, Blood Transfusions, Stem Cell Transplant, Splenectomy, Radiation Therapy, and Others), by Drug Type (Hydroxyurea, Immunomodulators, JAK Inhibitor, and Others), and by End-User (Hospitals, Clinics, and Bone Marrow Transplant Centers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024” . According to the report, global  myelofibrosis treatment market  was valued at approximately USD 621.5 million in 2017 and is expected to generate revenue of around USD 971.5 million by end of 2024, growing at CAGR of 6.73% between 2018 and 2024.

Myelofibrosis is rare bone marrow cancer in which normal bone marrow tissues get changed with scarred tissue which reduces the production of blood cells and increases the production of mutated cells. These mutated cells develop in different body organs, mostly in spleen due to overproduction of mutated cells thus leading to the enlargement of the spleen. This gives the feeling of fullness below the left lung; splenectomy is the procedure used to bring the spleen in its original shape and size. This disease leads to the reduction in the count of red blood cells with abnormalities such as different shapes of red blood cells, nucleated red blood cells, and others. In myelofibrosis patient, usually, platelets count decrease and increase in basophil count are observed during the blood test. This disease generally affects an individual after the age of 50 years. There is only one cure of this disease available and that is stem cell transplantation but this procedure involves several risks. Other treatment options also support in the treatment of myelofibrosis.

Browse through 119 Tables & 28 Figures spread over 110 Pages and in-depth TOC on "Global Myelofibrosis Treatment Market: Industry Type, Size, Share, Trends and Forecast, 2018 - 2024”.

Request Free Sample Report of Global Myelofibrosis Treatment Market Report @ https://www.zionmarketresearch.com/sample/mye...ent-market

Global myelofibrosis treatment market is primarily driven by the high prevalence of disease and an increase in R&D for the development of new and effective drug for the treatment and is expected to support the growth of myelofibrosis treatment market. Increased prevalence of the disease has increased the demand for treatment options. There are various drugs which are under development by different companies and it is expected that in the near future these drugs will be available and can be used for the treatment. Increase in the genetic disorder, reimbursement conditions, and increased healthcare facilities are expected to support the growth of myelofibrosis treatment market in the near future. However, lack of awareness and a high cost of treatment may slow down the growth of myelofibrosis treatment market over the forecast period.

The myelofibrosis treatment market is segmented on the basis of diagnosis type which includes gene mutation analysis, bone marrow biopsy, an imaging test, and blood test. Based on the treatment type, the myelofibrosis treatment market is segmented into chemotherapy, blood transfusions, stem cell transplant, splenectomy, radiation therapy, and others. Due to easy availability of chemotherapy agents, chemotherapy is expected to grow at a faster rate. On the basis of drug type, the myelofibrosis treatment market is segmented into hydroxyurea, immunomodulators, JAK inhibitors, and others. Based on the end user, the myelofibrosis treatment market is segmented into hospitals, clinics, and bone marrow transplant centers.

Download Free PDF Report Brochure:  https://www.zionmarketresearch.com/requestbro...ent-market

North America is the developed regional market for myelofibrosis treatment market and is expected to grow rapidly over the forecast period. The presence of developed countries such as the U.S., Canada, and others is driving the growth of the North America region. This growth is mainly due to the high prevalence of disease, high economic growth, high disposable income, well-developed healthcare facilities, increased awareness among people, and reimbursement of life-threatening diseases is very high in this region drives the growth of myelofibrosis treatment market.

Europe is the second largest market for myelofibrosis treatment and is expected to grow significantly over the forecast period. This growth is mainly supported by the high prevalence of disease and increased healthcare infrastructure in this region.

Browse the full  "Myelofibrosis Treatment Market by Diagnosis Type (Gene Mutation Analysis, Bone Marrow biopsy, Imaging Test, and Blood Tests), by Treatment Type (Chemotherapy, Blood Transfusions, Stem Cell Transplant, Splenectomy, Radiation Therapy, and Others), by Drug Type (Hydroxyurea, Immunomodulators, JAK Inhibitor, and Others), and by End-User (Hospitals, Clinics, and Bone Marrow Transplant Centers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024" report at  https://www.zionmarketresearch.com/report/mye...ent-market

The Asia Pacific is the third largest region for the myelofibrosis treatment market and it is expected to grow significantly over the forecast period. This growth is supported by various factors which include increase in the prevalence of disease, increase in healthcare facilities, increase in disposable income, and increase in geriatric population are expected to fuel the myelofibrosis treatment market.

Latin America and the Middle East & Africa are expected to show moderate growth over the forecast period due to the lack of awareness among people in this region, high treatment cost, and lack of healthcare facilities. Above mentioned factors are expected to fuel the growth of the myelofibrosis treatment market over the forecast period.

Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/my...ent-market

Some of the key players in myelofibrosis treatment market include Eli Lilly and Company, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Incyte Corporation, Merck & Co., Bristol-Myers Squibb Company, Novartis AG, Amgen Inc., and Celgene Corporation, among others.

Request customized copy of report @ https://www.zionmarketresearch.com/custom/3210

The report segments the global myelofibrosis treatment market as follows:

Global Myelofibrosis Treatment Market: Diagnosis Type Segment Analysis

  • Gene Mutation Analysis
  • Bone Marrow Biopsy
  • Imaging Test
  • Blood Test

Global Myelofibrosis Treatment Market: Treatment Type Segment Analysis

  • Chemotherapy
  • Blood Transfusions
  • Stem Cell Transplant
  • Splenectomy
  • Radiation Therapy
  • Others

Global Myelofibrosis Treatment Market: Drug Type Segment Analysis

  • Hydroxyurea
  • Immunomodulators
  • JAK Inhibitors
  • Others

Global Myelofibrosis Treatment Market: End-User Segment Analysis

  • Hospitals
  • Clinics
  • Bone Marrow Transplant Centers

Global Myelofibrosis Treatment Market: Regional Segment Analysis 

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • The Middle East and Africa

Related Reports:

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research Follow Us Twitter: https://twitter.com/zion_research

Blog: http://www.intenseresearch.com | http://www.mrsresearchgroup.com | http://www.marketresearchtrade.com | https://qyresearchgroup.com | http://marketnreports.com | https://zmrnewsjournal.us | http://www.e-marketresearch.com

Contact Us:

Joel John 244 Fifth Avenue, Suite N202 New York, 10001, United States Tel: +49-322 210 92714 USA/Canada Toll Free No.1-855-465-4651 Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

Blog: http://zmrblog.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PMET's High-Stakes Call on Shaakichiuwaanaan Update

Updated Category News Views 51

Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...

Continue Reading
Elong Kicks Off Central Asia Strategy with Almaty Launch

Updated Category News Views 70

Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 68

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
myKaarma's Off-Site Wash: A Game Changer for Dealers

Updated Category News Views 37

myKaarma Offers Time and Convenience Boost with Wash Option When was the last time a car dealership didn't have folks lined up waiting for a wash? Dragging out your car's service longer than a Sunday sermon. But today, myKaarma, the folks behind dealership customer interaction magic, cracked open another bottle of convenience with their latest offering: off-site,...

Continue Reading
Lyons Steers Home Services Brands to New Franchise Heights

Updated Category News Views 87

Big Changes Ahead for Home Franchise Concepts It's a fresh dawn over at Home Franchise Concepts, and Cory Lyons has been tapped to lead four pivotal brands as their new Brand President. Now, if you're looking at this lineup—Kitchen Tune-Up, Bath Tune-Up, The Tailored Closet, and PremierGarage—you know there's more than just nails and hammers involved. Lyons isn't just...

Continue Reading
Dixie Group Gears Up for Q3 Earnings Call Reveal

Updated Category News Views 105

Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...

Continue Reading
MoreBetter's Therapy Co-Investment: A Big Bet on Patient Data

Updated Category News Views 23

Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...

Continue Reading
Mass-Vac Unleashes Advanced Vacuum Protection

Updated Category News Views 92

Introducing a Heavy-Duty Defender for Lab Systems When it comes to safeguarding central laboratory vacuum systems, you can bet there’s more at play than meets the eye. Mass-Vac, Inc., steps up and doesn't mess around with their latest innovation—the MV Multi-Trap® Vacuum Inlet Trap. Climbing aboard in November 2026, this stout guardian against contamination is out to...

Continue Reading
Retail's AI Ambitions Clash with In-Store Data Realities

Updated Category News Views 127

AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...

Continue Reading
Gen Z, Millennials Lean on AI Amid Fiscal Crunch

Updated Category News Views 78

AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...

Continue Reading
ws Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles

Top 5 Most Recently Viewed Articles

Brookfield Asset Management Secures $750 Million Note Offering

Updated Category News Views 114

Brookfield Asset Management's Latest Offering of Notes Brookfield Asset Management Ltd. (“BAM”) (NYSE: BAM, TSX: BAM) has recently made headlines with its announcement regarding a public offering of $750 million in senior notes due 2055, featuring an attractive interest rate of 6.077% per annum. This strategic move showcases BAM's commitment to fortifying its...

Continue Reading
Xinjiang's Growth: A Bright Future Awaits Under New Strategies

Updated Category News Views 374

Xinjiang's Economic Evolution: A Time of Prosperity Xinjiang is currently witnessing an era of unparalleled growth and development. As highlighted in a recent white paper issued by the Information Office of the State Council, this region has embarked on a transformative journey. The focus on lawful governance, cultural integration, and economic fortification promises a...

Continue Reading
Understanding Short Selling Dynamics at Pinnacle Financial Partners

Updated Category News Views 125

Pinnacle Financial Partners' Recent Short Interest Trends Pinnacle Finl Partners's (NYSE: PNFP) short percent of float has seen a decline of 6.22% since its last report. The company announced that it now has 1.50 million shares sold short, constituting 1.96% of the total regular shares available for trading. Given the average trading volume, it would take traders roughly...

Continue Reading
MY DR NOW Expands in Gilbert Amid Doctor Shortage

Updated Category News Views 19

Addressing A Deficit in Primary Care In a world where finding a doctor feels harder than hitting the lottery, MY DR NOW just tossed a lifeline to Gilbert, Arizona. It's a town growing faster than weeds after a rainstorm. With its fifth clinic debuting, MY DR NOW is taking a swing at a problem gripping not just Gilbert, but the whole state: a critical shortage of primary...

Continue Reading
Legal Action Alert for Starbucks Corporation Shareholders

Updated Category News Views 98

Overview of the Class Action Lawsuit Against Starbucks Levi & Korsinsky, LLP has initiated a class action lawsuit for investors in Starbucks Corporation, trading under NASDAQ: SBUX. This legal action aims to recover losses experienced by shareholders due to alleged securities fraud. Understanding the specifics of this case and its implications for investors is crucial....

Continue Reading